secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRISPR Therapeutics AG (CRSP)
CIK:        0001674416
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055689
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CRISPR Therapeutics Q1 net loss widens to $116.6M; cash $2.1B after $280M offering and $200M milestone
--------------------------------------------------------------------------------

- Net loss of $116.6M in Q1 2024 vs $53.1M in Q1 2023; R&D expenses fell 24% to $76.2M.
- Ended March with $2.1B cash; includes $280M February direct offering and $200M CASGEVY milestone from Vertex.
- CASGEVY now approved in 5 regions; over 25 ATCs activated globally, multiple patients have cells collected.
- Next-gen CAR T CTX112 (CD19) and CTX131 (CD70) trials ongoing; preliminary CTX112 data expected this year.
- New in vivo programs CTX340 (hypertension) and CTX450 (porphyria) enter IND-enabling studies; clinical trials targeted for H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/0000950170-24-055689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674416/000095017024055689/crsp-20240508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer